Retatrutide vs Tirzepatide — Triple vs Dual Agonist Comparison
The Core Difference: Two Receptors vs Three
Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. Tirzepatide (Mounjaro/Zepbound) is a dual agonist that activates only GLP-1 and GIP receptors. The addition of glucagon receptor activation is what sets retatrutide apart — it introduces a direct energy expenditure pathway that promotes fat oxidation and reduces hepatic fat independently of appetite suppression.
Think of it this way: semaglutide pulls one lever (appetite). Tirzepatide pulls two (appetite + fat metabolism). Retatrutide pulls all three (appetite + fat metabolism + energy expenditure). Each additional receptor doesn't just add — it compounds the effect.
Head-to-Head Weight Loss Comparison
| Metric | Retatrutide (12mg) | Tirzepatide (15mg) |
|---|---|---|
| Trial name | TRIUMPH-4 (Phase 3) | SURMOUNT-1 (Phase 3) |
| Duration | 68 weeks | 72 weeks |
| Average weight loss | 28.7% / 71.2 lbs (32.3 kg) | 22.5% / ~52 lbs |
| Patients reaching 15%+ loss | ~80% | ~70% |
| Patients reaching 20%+ loss | ~70% | ~55% |
| Receptor targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP |
| FDA status | Phase 3 trials (not approved) | FDA approved |
| Developer | Eli Lilly | Eli Lilly |
The 28.7% weight loss from TRIUMPH-4 is the highest ever recorded in an obesity drug trial. For context, semaglutide (Wegovy) produces approximately 15% weight loss. Both retatrutide and tirzepatide are developed by Eli Lilly, and it's expected that retatrutide will eventually be positioned as the next step up for patients who need more aggressive weight loss or have plateaued on tirzepatide.
Mechanism of Action Breakdown
| Receptor | What It Does | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|---|
| GLP-1 | Reduces appetite, slows gastric emptying, improves insulin sensitivity | ✓ | ✓ | ✓ |
| GIP | Enhances fat metabolism, works synergistically with GLP-1 signaling | -- | ✓ | ✓ |
| Glucagon | Increases energy expenditure, promotes hepatic fat oxidation, raises metabolic rate | -- | -- | ✓ |
GLP-1 makes you eat less. GIP helps your body process fat more efficiently. Glucagon makes your body burn more energy even at rest. Tirzepatide gives you the first two. Retatrutide gives you all three — which is why it produces more weight loss with potentially better preservation of lean muscle mass.
Side Effects Comparison
| Side Effect | Tirzepatide | Retatrutide |
|---|---|---|
| Nausea | Common (especially during titration) | Common (more pronounced at 8mg+) |
| Decreased appetite | Very common | Very common (stronger) |
| Diarrhea | Common | Common |
| Constipation | Common | Common |
| Injection site reactions | Occasional | More common than tirzepatide |
| Vomiting | Occasional | Occasional (more common at higher doses) |
| Elevated heart rate | Rare | Occasional (5-12 bpm increase, dose-dependent) |
| Fatigue | Occasional | Occasional (more common in first 2 weeks at each dose) |
The glucagon receptor activation in retatrutide produces a somewhat different side effect profile. Users report that the 6mg to 8mg dose jump is where GI effects intensify most — similar to the semaglutide 0.5mg to 1.0mg transition. The heart rate increase (averaging 5-12 bpm) is unique to retatrutide and is attributed to the glucagon-mediated increase in metabolic rate. Most users find this tolerable and it stabilizes within a few weeks at each dose level.
Track tirzepatide or retatrutide — doses, weight, side effects, and blood levels in one app
- Log tirz or reta with pharmacokinetic blood level modeling
- Correlate weight, appetite, and side effects to dose changes
- Multi-compound support if you switch or stack
Cost Comparison: Compounded vs Brand-Name
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Brand-name (pharmacy) | $550-1,100/month (Mounjaro/Zepbound with insurance varies) | Not available (not approved) |
| Compounded | $150-350/month depending on dose and pharmacy | $200-450/month depending on source and dose |
| Insurance coverage | Possible (FDA-approved) | Not covered (investigational) |
| Availability | Widely available via prescription | Research/compounding only |
Tirzepatide has the significant advantage of FDA approval, which means insurance coverage is possible and the supply chain is regulated. Compounded retatrutide is sourced from compounding pharmacies or research suppliers, with varying quality and no insurance coverage. If cost and accessibility are primary factors, tirzepatide is the more practical choice today.
Switching from Tirzepatide to Retatrutide
"I've plateaued on tirzepatide — should I switch to retatrutide?" This is one of the most common questions in the GLP-1 community right now.
When Switching Makes Sense
- You've been on maximum tirzepatide dose (15mg) for 8+ weeks with stalled weight loss
- You've optimized diet, protein intake, and exercise and still plateaued
- You're working with a provider who can monitor your transition
The Switching Protocol (Community-Sourced)
| Step | Action |
|---|---|
| Week 0 | Take your last tirzepatide dose |
| Week 1 | Skip (washout period — both compounds have ~5-6 day half-lives) |
| Week 2 | Start retatrutide at 2mg regardless of your previous tirzepatide dose |
| Weeks 3-5 | Stay at 2mg — assess GI tolerance to the glucagon receptor |
| Week 6+ | Titrate up to 4mg, then follow standard titration (4 to 6 to 8 to 12mg every 4 weeks) |
Which One Should You Choose?
Choose Tirzepatide If:
- You want an FDA-approved, insurance-coverable medication
- You're starting your first GLP-1 compound
- You prefer a well-established safety profile with years of real-world data
- Your BMI is 30-40 and you're looking for 15-22% weight loss
- Cost and accessibility are important factors
Choose Retatrutide If:
- You've plateaued on tirzepatide or semaglutide
- You have a BMI of 40+ and need maximum weight loss
- You're comfortable using an investigational compound under provider supervision
- You specifically want the energy expenditure benefits of glucagon activation
- Muscle preservation during fat loss is a priority (e.g., you train regularly)
Regimen tracks both. Whether you're on tirzepatide, retatrutide, or transitioning between them, track your doses, weight, side effects, and blood levels in one place. Compare your protocols
Tracking Your Protocol
Whether you're sticking with tirzepatide or switching to retatrutide, tracking matters. Log every dose, track your weight trend, note side effects at each dose tier, and share your data with your provider. The Regimen app supports both compounds with pharmacokinetic blood level modeling — you can see exactly where your levels peak and trough throughout the week.
Related: Retatrutide Tracker | Tirzepatide Tracker | GLP-1 Dose Calculator | Split Dose Calculator
Frequently Asked Questions
Disclaimer: This article is for educational purposes only and is not medical advice. Retatrutide is not FDA-approved and is currently in Phase 3 clinical trials. Never switch medications without consulting your prescriber. Individual responses to these medications vary significantly.
Ready to track your protocol?
- Smart reminders so you never miss a dose
- Track weight, photos, and progress over time
- Medication level curves for every compound